A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma

By sjmartinez • March 7, 2025

Ellingson BM, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A, Sonni I, Chun S, Filka E, Yao J, Telesca D, Li S, Li G, Lai A, Nghiemphu P, Czernin J, Nathanson DA, Cloughesy TF. A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma. Neurooncol Adv. 2025 Feb 19;7(1):vdaf022. doi: 10.1093/noajnl/vdaf022. PMID: 40051661; PMCID: PMC11883343.

Tags: Cardiology/Epi, EGFR, FDG PET, Glioblastoma, imaging biomarker, molecular imaging, Osimertinib, Publications

Iron-Based Contrast for the Heart: Clinical Promise of Ferumoxytol-Enhanced CMR

Pogosyan A, Liu Y, Patel JA, Mahmoudi M, Xu H, Finn JP, Nguyen KL. Iron-Based Contrast for the Heart: Clinical Promise of Ferumoxytol-Enhanced CMR. Curr[...]

A New Frontier in Heart Failure: Promise and Pitfalls of Primary Prevention

Song MR, Ziaeian B. A New Frontier in Heart Failure: Promise and Pitfalls of Primary Prevention. JACC Heart Fail. 2026 Oct 28:103489. doi: 10.1016/j.jchf.2026.103489. Epub[...]

Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study

Sonni I, Mohammadigoldar Z, Furey G, Kimura K, Movva PC, Holzgreve A, Bahri S, Sevco T, Chung A, Sisk A, Grogan T, Czernin J, Sung[...]